Welcome to our dedicated page for Haemonetics Mass SEC filings (Ticker: HAE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Haemonetics’ diverse plasma, blood-center and hospital businesses mean its SEC disclosures can span hundreds of pages and multiple form types. If you have ever asked, “How do I find Haemonetics’ 10-K annual report?” or “Where are Haemonetics insider trading Form 4 transactions reported?”, you know the challenge: device approvals, consumable margins and segment revenue are scattered across dense filings.
Stock Titan solves this problem by pairing real-time EDGAR feeds with AI-powered summaries that translate regulatory language into plain English. Whether you need a Haemonetics quarterly earnings report 10-Q filing for revenue trends or an 8-K material events explained alert on a new TEG assay clearance, our platform highlights the numbers and footnotes that move valuations. Key documents are mapped to common investor questions:
- Form 4 – track Haemonetics executive stock transactions Form 4 in real time and spot buying or selling before major announcements.
- 10-Q – see segment margins, plasma-center growth and read a concise Haemonetics earnings report filing analysis.
- 10-K – get a Haemonetics annual report 10-K simplified view of long-term risks, FDA compliance and R&D pipelines.
- DEF 14A – review the latest Haemonetics proxy statement executive compensation details without searching page-by-page.
With AI explanations, keyword search and historical comparison tools, understanding Haemonetics SEC documents with AI becomes straightforward. Follow every Haemonetics Form 4 insider transactions real-time alert, compare quarter-over-quarter transfusion revenue, and export data for your models—no manual digging required.
Haemonetics (HAE) reported an insider share purchase on Form 4. A company director bought 1,400 shares of common stock at $70.56 on 11/10/2025. Following the transaction, the director’s direct beneficial ownership stands at 24,757 shares.
The ownership figure includes unvested restricted stock units that were previously reported. This filing records an open-market purchase by a board member and updates the director’s total holdings.
Haemonetics Corporation reported lower quarterly sales but stronger profitability. For the three months ended September 27, 2025, net revenues were $327.3 million versus $345.5 million a year ago, while gross profit rose to $194.7 million from $187.4 million as cost of goods sold declined. Operating income increased to $58.5 million, and net income was $38.7 million (diluted EPS $0.81) compared with $33.8 million ($0.66) last year.
For the six months ended September 27, 2025, net revenues were $648.7 million versus $681.7 million, and net income was $72.7 million, roughly flat year over year. Operating cash flow strengthened to $128.7 million from $21.4 million, supported by lower inventories and working capital changes.
The company recorded an $8.6 million impairment of certain Hospital business intangibles. It continued portfolio moves: completed the Whole Blood divestiture in January 2025 and executed a new ASR in August 2025, repurchasing $75.0 million of stock (1,430,579 shares at $52.43), leaving $425.0 million authorized under the 2025 program as of September 27, 2025. Shares outstanding were 46,809,672 as of October 31, 2025.
Haemonetics Corporation furnished a press release announcing financial results for the second quarter ended September 27, 2025 and the first half of fiscal 2026. The release is attached to a Form 8‑K as Exhibit 99.1 under Item 2.02. The company notes this information, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act, and is not incorporated by reference. The filing also includes the Inline XBRL cover page file as Exhibit 104.
Haemonetics (HAE) disclosed an insider Form 4 for its EVP, Chief Commercial Officer. On 10/31/2025, 145 shares of common stock were withheld for taxes upon RSU vesting (code F) at $50.01 per share. Following this transaction, the reporting person directly beneficially owns 12,811 shares. This total includes unvested RSUs and 24 shares acquired under the company’s Employee Stock Purchase Plan on October 31, 2025.
Haemonetics insider transaction summary: Laurie A. Miller, SVP, Human Resources at Haemonetics Corp (HAE), reported a Form 4 showing a tax-withholding disposition tied to the vesting of restricted stock units. On 09/17/2025, 238 shares were disposed (transaction code F) at a price of $49.95 per share to satisfy tax obligations related to vested RSUs. After that transaction, Ms. Miller beneficially owned 28,925 shares, which the filing notes includes unvested RSUs previously reported. The Form 4 was signed by attorney-in-fact Thomas V. Powers on 09/24/2025.
FAQ
What is the current stock price of Haemonetics Mass (HAE)?
What is the market cap of Haemonetics Mass (HAE)?
